237 related articles for article (PubMed ID: 37705397)
1. Long-term impact of angiotensin receptor-neprilysin inhibitor based on short-term treatment response in heart failure.
Park HK; Park JS; Kim MS; Lee E; Choi H; Park YJ; Park BE; Kim HN; Kim N; Bae MH; Lee JH; Park HS; Cho Y; Jang SY; Yang DH
ESC Heart Fail; 2023 Dec; 10(6):3430-3437. PubMed ID: 37705397
[TBL] [Abstract][Full Text] [Related]
2. Effect of angiotensin receptor neprilysin inhibitors on left atrial remodeling and prognosis in heart failure.
Sun Y; Song S; Zhang Y; Mo W; Zhang X; Wang N; Xia Y; Tse G; Liu Y
ESC Heart Fail; 2022 Feb; 9(1):667-675. PubMed ID: 34779134
[TBL] [Abstract][Full Text] [Related]
3. Real-world use patterns of angiotensin receptor-neprilysin inhibitor (sacubitril/valsartan) among patients with heart failure within a large integrated health system.
Kim BJ; Huang CW; Chung J; Neyer JR; Liang B; Yu AS; Kwong EK; Park JS; Hung P; Sim JJ
J Manag Care Spec Pharm; 2022 Oct; 28(10):1173-1179. PubMed ID: 36125061
[No Abstract] [Full Text] [Related]
4. Estimated 5-Year Number Needed to Treat to Prevent Cardiovascular Death or Heart Failure Hospitalization With Angiotensin Receptor-Neprilysin Inhibition vs Standard Therapy for Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of Data From the PARADIGM-HF Trial.
Srivastava PK; Claggett BL; Solomon SD; McMurray JJV; Packer M; Zile MR; Desai AS; Rouleau JL; Swedberg K; Fonarow GC
JAMA Cardiol; 2018 Dec; 3(12):1226-1231. PubMed ID: 30484837
[TBL] [Abstract][Full Text] [Related]
5. Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction.
Martin N; Manoharan K; Davies C; Lumbers RT
Cochrane Database Syst Rev; 2021 May; 5(5):CD012721. PubMed ID: 34022072
[TBL] [Abstract][Full Text] [Related]
6. Characterization of heart failure patients with reverse left ventricular remodelling post-angiotensin receptor blockers/neprilysin inhibitors therapy.
Maizels L; Wasserstrum Y; Fishman B; Segev A; Ben-Nun D; Younis A; Freimark D; Mazin I; Grupper A
ESC Heart Fail; 2022 Jun; 9(3):1682-1688. PubMed ID: 35178886
[TBL] [Abstract][Full Text] [Related]
7. Sodium-Glucose Cotransporter 2 Inhibitors First Strategy Improve Decongestion in Patients with Symptomatic Heart Failure and Reduced Ejection Fraction When Compared to Angiotensin Receptor Neprilysin Inhibitor First Strategy.
Lee WC; Chang WT; Hong CS; Liao CT; Huang PS; Huang SC; Lin CH; Chiang CY; Chen ZC; Shih JY
Front Biosci (Landmark Ed); 2023 Apr; 28(4):81. PubMed ID: 37114551
[TBL] [Abstract][Full Text] [Related]
8. Real-World Experience of Angiotensin Receptor-Neprilysin Inhibition in Reduced Ejection Fraction Heart Failure Patients With Advanced Kidney Disease.
Chang HY; Lin CC; Chao CJ; Lin YC; Wang YC; Liao CT; Huang JL; Lee YH; Huang CY; Chien LN; Hsu CY
Mayo Clin Proc; 2023 Jan; 98(1):88-99. PubMed ID: 36109207
[TBL] [Abstract][Full Text] [Related]
9. Effect of the angiotensin-receptor-neprilysin inhibitor in heart failure patients with left ventricular ejection fraction higher than 40.
Zhao M; Xin Y; Li J; Cao X; Liu X
Medicine (Baltimore); 2019 Sep; 98(39):e17296. PubMed ID: 31574852
[TBL] [Abstract][Full Text] [Related]
10. Angiotensin Receptor Neprilysin Inhibitor for Patients With Heart Failure and Reduced Ejection Fraction: Real-World Experience From Taiwan.
Hsiao FC; Wang CL; Chang PC; Lu YY; Huang CY; Chu PH
J Cardiovasc Pharmacol Ther; 2020 Mar; 25(2):152-157. PubMed ID: 31514513
[TBL] [Abstract][Full Text] [Related]
11. Angiotensin Receptor-Neprilysin Inhibitors in Patients With Heart Failure With Reduced Ejection Fraction and Advanced Chronic Kidney Disease: A Retrospective Multi-Institutional Study.
Hsiao FC; Lin CP; Yu CC; Tung YC; Chu PH
Front Cardiovasc Med; 2022; 9():794707. PubMed ID: 35360037
[TBL] [Abstract][Full Text] [Related]
12. Guideline-Directed Medical Therapy in Newly Diagnosed Heart Failure With Reduced Ejection Fraction in the Community.
Dunlay SM; Killian JM; Roger VL; Schulte PJ; Blecker SB; Savitz ST; Redfield MM
J Card Fail; 2022 Oct; 28(10):1500-1508. PubMed ID: 35902033
[TBL] [Abstract][Full Text] [Related]
13. Treatment Persistence of Renin-Angiotensin-Aldosterone-System Inhibitors Over Time in Heart Failure with Reduced Ejection Fraction.
Vaduganathan M; Fonarow GC; Greene SJ; Devore AD; Albert NM; Duffy CI; Hill CL; Patterson JH; Spertus JA; Thomas LE; Williams FB; Hernandez AF; Butler J
J Card Fail; 2022 Feb; 28(2):191-201. PubMed ID: 34428591
[TBL] [Abstract][Full Text] [Related]
14. Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial.
Solomon SD; Claggett B; Desai AS; Packer M; Zile M; Swedberg K; Rouleau JL; Shi VC; Starling RC; Kozan Ö; Dukat A; Lefkowitz MP; McMurray JJ
Circ Heart Fail; 2016 Mar; 9(3):e002744. PubMed ID: 26915374
[TBL] [Abstract][Full Text] [Related]
15. Titration of medications and outcomes in multi-ethnic heart failure cohorts (with reduced ejection fraction) from Singapore and New Zealand.
Teng TK; Tay WT; Ouwerkerk W; Tromp J; Richards AM; Gamble G; Greene SJ; Yiu KH; Poppe K; Ling LH; Lund M; Sim D; Devlin G; Loh SY; Troughton R; Ren QW; Jaufeerally F; Lee SGS; Tan RS; Soon DKN; Leong G; Ong HY; Yeo DPS; Lam CSP; Doughty RN
ESC Heart Fail; 2023 Apr; 10(2):1280-1293. PubMed ID: 36722315
[TBL] [Abstract][Full Text] [Related]
16. Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials.
Vaduganathan M; Claggett BL; Jhund PS; Cunningham JW; Pedro Ferreira J; Zannad F; Packer M; Fonarow GC; McMurray JJV; Solomon SD
Lancet; 2020 Jul; 396(10244):121-128. PubMed ID: 32446323
[TBL] [Abstract][Full Text] [Related]
17. Effects of angiotensin receptor-neprilysin inhibitor on insulin resistance in patients with heart failure.
Kashiwagi Y; Nagoshi T; Kimura H; Tanaka Y; Oi Y; Inoue Y; Ogawa K; Kawai M; Yoshimura M
ESC Heart Fail; 2023 Jun; 10(3):1860-1870. PubMed ID: 36942494
[TBL] [Abstract][Full Text] [Related]
18. Effects of the Angiotensin-Receptor Neprilysin Inhibitor on Cardiac Reverse Remodeling: Meta-Analysis.
Wang Y; Zhou R; Lu C; Chen Q; Xu T; Li D
J Am Heart Assoc; 2019 Jul; 8(13):e012272. PubMed ID: 31240976
[TBL] [Abstract][Full Text] [Related]
19. Comparative Effectiveness of Dosing of Medical Therapy for Heart Failure: From the CHAMP-HF Registry.
Greene SJ; Butler J; Hellkamp AS; Spertus JA; Vaduganathan M; Devore AD; Albert NM; Patterson JH; Thomas L; Williams FB; Hernandez AF; Fonarow GC
J Card Fail; 2022 Mar; 28(3):370-384. PubMed ID: 34793971
[TBL] [Abstract][Full Text] [Related]
20. Higher versus lower doses of ACE inhibitors, angiotensin-2 receptor blockers and beta-blockers in heart failure with reduced ejection fraction: Systematic review and meta-analysis.
Turgeon RD; Kolber MR; Loewen P; Ellis U; McCormack JP
PLoS One; 2019; 14(2):e0212907. PubMed ID: 30817783
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
